Indication
In adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils (EOS) on a combination of an inhaled corticosteroid (ICS), a long-acting beta2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA), or on a combination of a LABA and a LAMA, if ICS is not appropriate.
Medicine details
- Medicine name:
- dupilumab (Dupixent)
- SMC ID:
- SMC2945
- Pharmaceutical company
- Sanofi
- BNF chapter
- Respiratory system
- Submission type
- Resubmission
- Publication due date:
- TBC
- SMC meeting date:
- TBC
- Patient group submission deadline:
- TBC